FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.

被引：0
|
作者：
Smyth, Elizabeth Catherine
Turner, Nicholas C.
Popat, Sanjay
Morgan, Shethah
Owen, Kate
Gillbanks, Angela
Jain, Vikram Kumar
Cunningham, David
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, London, England
[2] AstraZeneca, Macclesfield, Cheshire, England
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2626
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
    Kwak, Yeonui
    Cho, Hanna
    Hur, Wooyoung
    Sim, Taebo
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2292 - 2302
  • [32] Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3
    Gayine, Paul R.
    Mooney, Lorraine
    Kilgour, Elaine
    Thomas, Andrew P.
    Al-Kadhimi, Katherine
    Beck, Sarah
    Coleman, Tanya
    Baker, Dawn
    Mellor, Martine J.
    Brooks, Nigel A. N.
    Klinowska, Teresa
    CANCER RESEARCH, 2011, 71
  • [33] Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
    Tsimafeyeu, Ilya
    Demidov, Lev
    Stepanova, Eugenia
    Wynn, Nigel
    Ta, Hung
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2011, 45 (03): : 190 - 195
  • [34] Expression and localization of FGFR1, FGFR2 and CTGF during normal human lung development
    Kolobaric, Anita
    Vukojevic, Katarina
    Brekalo, Svjetlana
    Miskovic, Josip
    Ries, Mihael
    Arapovic, Lidija Lasic
    Soljic, Violeta
    ACTA HISTOCHEMICA, 2021, 123 (05)
  • [35] Distinct Requirements for FGFR1 and FGFR2 in Primitive Endoderm Development and Exit from Pluripotency
    Molotkov, Andrei
    Mazot, Pierre
    Brewer, J. Richard
    Cinalli, Ryan M.
    Soriano, Philippe
    DEVELOPMENTAL CELL, 2017, 41 (05) : 511 - +
  • [36] Spatial distribution and functional relevance of FGFR1 and FGFR2 expression for glioblastoma tumor invasion
    Alshahrany, Nawal
    Begum, Ayesha
    Siebzehnrubl, Dorit
    Jimenez-Pascual, Ana
    Siebzehnrubl, Florian A.
    CANCER LETTERS, 2023, 571
  • [37] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Zuo-wei Wang
    Feng-ming Zou
    Ao-li Wang
    Jing Yang
    Rui Jin
    Bei-lei Wang
    Li-juan Shen
    Shuang Qi
    Juan Liu
    Jing Liu
    Wen-chao Wang
    Qing-song Liu
    Acta Pharmacologica Sinica, 2023, 44 : 801 - 810
  • [38] Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
    Chang, Jinjia
    Wang, Shanshan
    Zhang, Zhe
    Liu, Xinyang
    Wu, Zheng
    Geng, Ruixuan
    Ge, Xiaoxiao
    Dai, Congqi
    Liu, Rujiao
    Zhang, Qunling
    Li, Wenhua
    Li, Jin
    ONCOTARGET, 2015, 6 (04) : 2009 - 2022
  • [39] Ureteric Morphogenesis Requires Fgfr1 and Fgfr2/Frs2α Signaling in the Metanephric Mesenchyme
    Sims-Lucas, Sunder
    Di Giovanni, Valeria
    Schaefer, Caitlin
    Cusack, Brian
    Eswarakumar, Veraragavan P.
    Bates, Carlton M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (04): : 607 - 617
  • [40] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Wang, Zuo-wei
    Zou, Feng-ming
    Wang, Ao-li
    Yang, Jing
    Jin, Rui
    Wang, Bei-lei
    Shen, Li-juan
    Qi, Shuang
    Liu, Juan
    Liu, Jing
    Wang, Wen-chao
    Liu, Qing-song
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (04): : 801 - 810
12345